Published in Biotech Law Weekly, July 23rd, 2004
Alaris will have to show cause why Alaris "should not be restrained and enjoined pending trial of this matter from making, using, selling, or offering to sell Alaris' SmartSite and SmartSite Plus needle-free valves and systems in the United States; or importing Alaris' SmartSite and SmartSite Plus needle-free valves and systems in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.